NasdaqGM - Nasdaq Real Time Price USD
Altimmune, Inc. (ALT)
As of 1:32 PM EST. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 5 | 5 | 7 |
| Avg. Estimate | -0.34 | -0.38 | -1.35 | -1.12 |
| Low Estimate | -0.39 | -0.42 | -1.4 | -1.97 |
| High Estimate | -0.27 | -0.33 | -1.28 | 0.73 |
| Year Ago EPS | -0.33 | -0.34 | -1.43 | -1.35 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 5 | 9 | 9 |
| Avg. Estimate | 620 | 1k | 5k | 22.22M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 5k | 5k | 20k | 200M |
| Year Ago Sales | 37k | 5k | 426k | 5k |
| Sales Growth (year/est) | -98.32% | -80.00% | -98.83% | 444,388.82% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.38 | -0.35 | -0.34 | -0.36 |
| EPS Actual | -0.33 | -0.34 | -0.35 | -0.32 |
| Difference | 0.05 | 0.01 | -0.01 | 0.04 |
| Surprise % | 14.20% | 3.55% | -1.45% | 10.49% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.38 | -1.35 | -1.12 |
| 7 Days Ago | 0.24 | -0.34 | -0.8 | -1.09 |
| 30 Days Ago | 0.24 | -0.34 | -0.8 | -1.09 |
| 60 Days Ago | 0.24 | -0.34 | -0.8 | -1.09 |
| 90 Days Ago | 0.34 | -0.34 | -0.79 | -1.09 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 3 |
| Down Last 7 Days | 1 | 2 | 2 | 1 |
| Down Last 30 Days | 1 | 2 | 2 | 2 |
Growth Estimates
| CURRENCY IN USD | ALT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -4.70% | -- | -- | 5.00% |
| Next Qtr. | -11.12% | -- | -- | 12.00% |
| Current Year | 5.31% | -- | -- | 2.10% |
| Next Year | 17.35% | -- | -- | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2024 |
| Initiated | UBS: Buy | 11/12/2024 |
| Reiterates | B. Riley Securities: Buy to Buy | 8/12/2024 |
| Reiterates | B. Riley Securities: Buy to Buy | 6/25/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 6/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
Related Tickers
VKTX Viking Therapeutics, Inc.
54.00
+4.79%
MDGL Madrigal Pharmaceuticals, Inc.
328.47
+3.59%
IOVA Iovance Biotherapeutics, Inc.
8.34
+2.46%
TERN Terns Pharmaceuticals, Inc.
5.78
+3.21%
TGTX TG Therapeutics, Inc.
35.05
+12.52%
IBRX ImmunityBio, Inc.
5.10
+4.51%
SAVA Cassava Sciences, Inc.
31.66
+21.67%
GPCR Structure Therapeutics Inc.
31.29
-4.34%
NTLA Intellia Therapeutics, Inc.
14.36
+9.45%
SMMT Summit Therapeutics Inc.
19.08
+2.47%